Role of T Lymphocyte Activation Profile in Predicting SARS-CoV-2 Severity: Experience from Tertiary Care Centre of North India

[1]  Sanjeev,et al.  Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care centre in India , 2021, Annals of Hematology.

[2]  M. Voso,et al.  Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study , 2021, Scientific Reports.

[3]  T. Tabuchi,et al.  Coronavirus Disease , 2021, Encyclopedia of the UN Sustainable Development Goals.

[4]  C. Yao,et al.  Cell-Type-Specific Immune Dysregulation in Severely Ill COVID-19 Patients , 2020, Cell Reports.

[5]  W. Wood,et al.  Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients , 2020, Blood.

[6]  C. Yao,et al.  Cell type-specific immune dysregulation in severely ill COVID-19 patients , 2020, medRxiv.

[7]  Sasikanth Manne,et al.  Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications , 2020, Science.

[8]  Inkyung Jung,et al.  Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19 , 2020, Science Immunology.

[9]  C. Agrati,et al.  Immunological and inflammatory profiles in mild and severe cases of COVID-19 , 2020, Nature Communications.

[10]  C. D. Dela Cruz,et al.  Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19 , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[11]  M. Merad,et al.  Immunology of COVID-19: Current State of the Science , 2020, Immunity.

[12]  Li Yang,et al.  Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[13]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[14]  C. Hedrich,et al.  COVID-19: Immunology and treatment options , 2020, Clinical Immunology.

[15]  M. Girardis,et al.  Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia , 2020, Nature Communications.

[16]  Hongming Miao,et al.  Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study , 2020, Signal Transduction and Targeted Therapy.

[17]  Bo Diao,et al.  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.

[18]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[20]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[21]  T. Gao,et al.  The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination , 2017, Journal of Virology.

[22]  C. Chiu,et al.  Antiviral B cell and T cell immunity in the lungs , 2014, Nature Immunology.